Impact of combined hormonal therapy on coagulation inhibitory proteins

The objective of this study was to determine the effect of two combined oral contraceptives on two inhibitory coagulation proteins. The study included 56 women between ages 20 and 55, twenty six of them taking 30?g ethinyloestradiol (EE) and 75?g gestodene (GSD) and thirty of them taking 30 ?g ethinyloestradiol and 75 ?g levonogestrel (LNG) for two months. The subjects were healthy and they had not taken any other drug two months before starting the hormonal therapy. Plasma was used for measuring protein C and antithrombin III (AT III), before using the pill and after stopping it. Comparison of the values of protein C and AT III between two periods (before and after treatment) showed the following results: Concentrations of protein C was significantly increased while AT III level was decreased after treatment with 30 ?g EE/ 75 ?g GSD (p=0.001). Treatment with 30 ?g EE/ 75 ?g LNG showed no significant change in the level of AT III (p=0.058) and significantly increased protein C concentration (p=0.001). We conclude that treatment with 30 ?g EE/ 75 ?g GSD induces more changes in the inhibitory coagulation proteins than treatment with 30 ?g EE/ 75 ?g LNG, indicating an increased risk for thrombotic diseases.

___

1. World Health Organization. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.

2. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.

3. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371- 1380.

4. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002; 81: 482-490.

5. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 2004; 103: 927-933.

6. Walker ID, Greaves M, Preston FE. On behalf of the Haemostasis and Thrombosis Task Force British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia Br J Haematol 2001; 114: 512-528.

7. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deepvein thrombosis. Lancet 1995; 345: 152-155.

8. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deepvein thrombosis. N Engl J Med 1996; 334: 759-762.

9. Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115: 767-773.

10. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 3863-3870.

11. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: 2921.

12. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.

13. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.

14. Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system. Contraception 1997; 56: 67-75.

15. J Jespersen KR, Petersen SO. Skouby Coagulation and fibrinolysis comparison study of two new lowdose oral contraceptives Adv Contraception, 7 1991; pp. 292-296.

16. Winkler UH, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care 1999; 4: 145- 154.

17. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.